Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antigen-presenting cell (APC) activation via the MHC class I pathway is a critical process in the adaptive immune response, enabling cytotoxic T lymphocytes (CD8+ T cells) to recognize and eliminate infected or abnormal cells. This pathway involves the presentation of endogenous antigens—typically derived from intracellular pathogens like viruses or from mutated proteins in cancerous cells—on MHC class I molecules at the surface of nearly all nucleated cells. It facilitates immune surveillance and targeted destruction of compromised cells. The pathway involves antigen processing by the proteasome, transport of peptides into the ER by TAP, peptide loading onto MHC-I with the help of chaperones, and surface expression of the peptide-MHC-I complex for T cell recognition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen-Presenting Cell Activation via MHC Class I Pathway (MHC-I Antigen Presentation).